{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-26-000055","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2026-08-13T20:59:21+00:00","discovered_at":"2026-08-13T21:00:00.610597+00:00","generated_at":"2026-08-13T21:00:07.753216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Instil Bio Q2 2026 net loss $0.63/share; cash $69.9M funds beyond 2027","bullets":["Cash, equivalents, restricted cash and marketable securities $69.9M at June 30, 2026, down from $76.3M at Dec 31, 2025.","Q2 2026 net loss per share $0.63 (basic/diluted) vs $3.24 in Q2 2025; non-GAAP $0.45 vs $2.88.","R&D expenses $0.3M in Q2 2026 vs $6.7M in Q2 2025; G&A $5.1M vs $6.2M.","In-process R&D expenses nil vs $10.0M in Q2 2025; restructuring charges $0.2M vs $0.5M.","Company evaluating potential acquisitions, in-licensing opportunities for novel therapeutic candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-26-000055","json":"https://secwatch.observer/filing/0001789769-26-000055.json","markdown":"https://secwatch.observer/filing/0001789769-26-000055.md","text":"https://secwatch.observer/filing/0001789769-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/0001789769-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/til-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T21:00:07.753216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}